Titan Pharmaceuticals, Inc. (de) (NASDAQ: TTNP)’s stock price has gone rise by 21.94 in comparison to its previous close of 3.14, however, the company has experienced a 14.82% increase in its stock price over the last five trading days. https://www.marketscreener.com reported 2024-12-09 that Lundin Mining Announces Sale to Boliden of its Neves-Corvo operation in Portugal and Zinkgruvan operation in Sweden for Up to $1.52 Billion: Lundin To Receive Upfront Cash Consideration of $1.37B Upon Closing; To Also Get up to $150M in Contingent Cash Upon Satisfaction of Condition; Proceeds Will Strengthen Balance Sheet and Support Growth Plans in the Vicuña District Expected Major Events for Monday aAdsList.push(‘Article’); aAdsListSize.push([300, 250]); aAdsListCA.push(null); 00:01/UK: Nov KPMG and REC UK Report on Jobs 04:30/JPN: Nov Corporate Insolvencies 05:00/JPN: Nov Economy Watchers Survey 07:00/GER: 3Q Labour cost index 15:00/US: Oct Monthly Wholesale Trade 15:00/US: Nov Employment Trends Index 23:50/JPN: Nov Money Stock, Broadly-defined Liquidity All times in GMT. Powered by Kantar Media and Dow Jones. Expected Earnings for Monday Amtech Systems Inc (ASYS) is expected to report $-0.01 for 4Q. Anavex Life Sciences Corp (AVXL) is expected to report $-0.16 for 4Q. Avalon Advanced Materials is expected to report for 4Q. Braze Inc (BRZE) is expected to report $-0.30 for 3Q. Buckle Inc (BKE) is expected to report. C3.ai Inc (AI) is expected to report $-0.60 for 2Q. Casey’s General Stores Inc (CASY) is expected to report $4.25 for 2Q. Centene Corp (CNC) is expected to report for Full year. Digital Ally Inc (DGLY) is expected to report for 3Q. Franklin Resources Inc (BEN) is expected to report. Genasys Inc (GNSS) is expected to report $-0.11 for 4Q. Healthequity Inc (HQY) is expected to report $0.24 for 3Q. MongoDB Inc (MDB) is expected to report $-0.83 for 3Q. NexPoint Diversified Real Estate Trust (NXDT) is expected to report for 3Q. North West Co Inc (NWC.T) is expected to report $0.77 for 3Q. Oil-Dri Corp of America (ODC) is expected to report for 1Q. Oracle Corp (ORCL) is expected to report $1.06 for 2Q. Phreesia Inc (PHR) is expected to report $-0.27 for 3Q. Planet Labs PBC (PL) is expected to report $-0.08 for 3Q. Remark Holdings Inc (MARK) is expected to report $-0.19 for 3Q. Rent the Runway Inc (RENT) is expected to report for 3Q. Smart Share Global Ltd – ADR (EM) is expected to report for 3Q. Talis Biomedical Corp (TLIS) is expected to report for 3Q. Titan Pharmaceuticals Inc (TTNP) is expected to report for 3Q. Toll Brothers Inc (TOL) is expected to report $4.34 for 4Q. Vail Resorts (MTN) is expected to report $-4.96 for 1Q. VersaBank is expected to report $0.29 for 4Q. Webco Industries Inc (WEBC) is expected to report for 1Q. Yext Inc (YEXT) is expected to report $0.06 for 3Q. Powered by Kantar Media and Dow Jones. ANALYST RATINGS ACTIONS Altria Raised to Buy From Neutral by B of A Securities Argan Cut to Market Perform From Market Outperform by CJS Securities Asana Raised to Sector Weight From Underweight by Keybanc Brixmor Property Group Raised to Outperform From Market Perform by BMO Capital Deere & Co Cut to Hold From Buy by Jefferies DocuSign Cut to Reduce From Hold by HSBC Dollar General Raised to Buy From Underperform by B of A Securities Duckhorn Portfolio Cut to Hold From Buy by Jefferies EPAM Systems Raised to Buy From Neutral by Goldman Sachs Fortrea Holdings Cut to Neutral From Outperform by Baird GrafTech International Raised to Neutral From Underweight by JP Morgan Hewlett Packard Ent Raised to Buy From Neutral by Citigroup Kennametal Cut to Hold From Buy by Jefferies Molson Coors Beverage Raised to Buy From Neutral by B of A Securities ONE Gas Cut to Neutral From Buy by Ladenburg Thalmann Paccar Cut to Hold From Buy by Jefferies Peloton Interactive Raised to Neutral From Sell by UBS PJT Partners Raised to Neutral From Sell by UBS PotlatchDeltic Raised to Outperform From Market Perform by BMO Capital ProFrac Holding Cut to Underweight From Neutral by JP Morgan Prologis Cut to Underperform From Market Perform by BMO Capital ProPetro Holding Raised to Neutral From Underweight by JP Morgan Republic Services Raised to Outperform From Market Perform by BMO Capital Robinhood Markets Raised to Buy From Neutral by Goldman Sachs SiteOne Landscape Supply Raised to Buy From Hold by Jefferies Smith & Wesson Brands Cut to Hold From Buy by Craig-Hallum Smith & Wesson Brands Cut to Hold From Buy by Lake Street Timken Raised to Buy From Hold by Jefferies WesBanco Raised to Strong Buy From Outperform by Raymond James Weyerhaeuser Raised to Outperform From Market Perform by BMO Capital This article is a text version of a Wall Street Journal newsletter published earlier today. (END) Dow Jones Newswires 12-09-24 0634ET
Is It Worth Investing in Titan Pharmaceuticals, Inc. (de) (NASDAQ: TTNP) Right Now?
The stock has a 36-month beta value of 1.14. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for TTNP is 0.65M, and at present, short sellers hold a 1.97% of that float. On January 20, 2025, the average trading volume of TTNP was 24.05K shares.
TTNP’s Market Performance
TTNP’s stock has seen a 14.82% increase for the week, with a 13.13% rise in the past month and a -20.76% fall in the past quarter. The volatility ratio for the week is 10.04%, and the volatility levels for the past 30 days are at 10.05% for Titan Pharmaceuticals, Inc. (de) The simple moving average for the past 20 days is 14.25% for TTNP’s stock, with a -29.21% simple moving average for the past 200 days.
Analysts’ Opinion of TTNP
Many brokerage firms have already submitted their reports for TTNP stocks, with Maxim Group repeating the rating for TTNP by listing it as a “Buy.” The predicted price for TTNP in the upcoming period, according to Maxim Group is $4 based on the research report published on June 26, 2019 of the previous year 2019.
TTNP Trading at 5.38% from the 50-Day Moving Average
After a stumble in the market that brought TTNP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -74.09% of loss for the given period.
Volatility was left at 10.05%, however, over the last 30 days, the volatility rate increased by 10.04%, as shares surge +11.48% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -4.84% lower at present.
During the last 5 trading sessions, TTNP rose by +14.82%, which changed the moving average for the period of 200-days by -48.11% in comparison to the 20-day moving average, which settled at $3.36. In addition, Titan Pharmaceuticals, Inc. (de) saw 17.64% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for TTNP
Current profitability levels for the company are sitting at:
- -71.88 for the present operating margin
- 0.9 for the gross margin
The net margin for Titan Pharmaceuticals, Inc. (de) stands at -72.67. The total capital return value is set at -1.8. Equity return is now at value -103.60, with -86.55 for asset returns.
Currently, EBITDA for the company is -7.17 million with net debt to EBITDA at 0.58. When we switch over and look at the enterprise to sales, we see a ratio of 1.32. The receivables turnover for the company is 2.13for trailing twelve months and the total asset turnover is 0.02. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.71.
Conclusion
To sum up, Titan Pharmaceuticals, Inc. (de) (TTNP) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
